Influence of UHMWPE content on swelling pressure. by Yonggang Huang (223155)

“…When the UHMWPE content exceeds 0.3% the weight of the soil, there is no significant decrease in the swelling pressure of the reinforced soil (<i>p</i> = 0.052, close to the threshold of significance). …”

Soil partice-size distribution. by Yonggang Huang (223155)

“…When the UHMWPE content exceeds 0.3% the weight of the soil, there is no significant decrease in the swelling pressure of the reinforced soil (<i>p</i> = 0.052, close to the threshold of significance). …”

<i>CTSZ</i> SNPs significantly associated with TB severity in Ugandan household contact study cohorts, sorted by ascending <i>p</i>-value. by Rachel K. Meade (22216529)

Development of a CRISPR/Cas-Based Detection Platform for Tracking Decreased Susceptibility to Cephalosporins in Neisseria gonorrheae by Ziyuan Zhao (2889005)

“…Developing efficient and accurate detection of resistant strains is urgently needed for their management and treatment. We have developed the Multiplex Integrated RPA-CRISPR/Cas12a detection Assay (MIRCA) for simultaneous detection of Neisseria gonorrheae (<i>Ng</i>) and mutations with decreased susceptibility to cephalosporins. …”

Vasopressor titration regimen in the balanced multimodal group. by Žiga Kalamar (22145810)

Subjects:

The schedule of enrollment, interventions and assessments. by Žiga Kalamar (22145810)

Subjects:

Descriptive statistics (means) for full sample and by lockdown status. by Drew B. Cameron (10687420)

Subjects:

Study sites and number of participants enrolled in the KAP and OOP surveys. by Drew B. Cameron (10687420)

Subjects:

Average cost per visit for HIV and HTN care (absolute vs. relative contributions). by Drew B. Cameron (10687420)

Subjects:

GLM models for predictors of monthly HTN care costs. by Drew B. Cameron (10687420)

Subjects:

Median monthly care costs, projected visits, and hospitalization costs. by Drew B. Cameron (10687420)

Subjects:

Study Flowchart. by Jae-Heung Cho (798319)

Subjects:

Changes in outcomes over time. by Jae-Heung Cho (798319)

Subjects:

Study timetable. by Jae-Heung Cho (798319)

Subjects:

Cumulative incidence curves of recovery by group. by Jae-Heung Cho (798319)

Subjects:

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects: